Cardlytics, Inc. (NASDAQ:CDLX – Get Free Report) has earned a consensus recommendation of “Hold” from the seven analysts that are presently covering the stock, MarketBeat reports. One analyst has rated the stock with a sell recommendation, five have issued a hold recommendation and one has issued a strong buy recommendation on the company. The average 12-month price target among brokerages that have issued a report on the stock in the last year is $6.92.
CDLX has been the subject of a number of research analyst reports. Craig Hallum raised shares of Cardlytics from a “hold” rating to a “strong-buy” rating in a research note on Wednesday, November 6th. Needham & Company LLC restated a “hold” rating on shares of Cardlytics in a research report on Friday, January 17th. Finally, Evercore ISI initiated coverage on Cardlytics in a research report on Friday, October 11th. They issued an “in-line” rating and a $4.00 price objective on the stock.
Check Out Our Latest Research Report on Cardlytics
Insiders Place Their Bets
Hedge Funds Weigh In On Cardlytics
A number of hedge funds and other institutional investors have recently made changes to their positions in the company. GSA Capital Partners LLP raised its stake in Cardlytics by 1,273.2% during the 3rd quarter. GSA Capital Partners LLP now owns 382,315 shares of the company’s stock worth $1,223,000 after buying an additional 354,474 shares during the period. RBF Capital LLC lifted its holdings in shares of Cardlytics by 311.9% during the 3rd quarter. RBF Capital LLC now owns 488,128 shares of the company’s stock valued at $1,562,000 after purchasing an additional 369,620 shares in the last quarter. Geode Capital Management LLC grew its position in shares of Cardlytics by 7.5% in the 3rd quarter. Geode Capital Management LLC now owns 1,053,178 shares of the company’s stock valued at $3,371,000 after purchasing an additional 73,484 shares during the period. Barclays PLC increased its stake in Cardlytics by 223.9% during the 3rd quarter. Barclays PLC now owns 58,026 shares of the company’s stock worth $186,000 after purchasing an additional 40,112 shares in the last quarter. Finally, SG Americas Securities LLC acquired a new stake in Cardlytics during the 3rd quarter worth approximately $45,000. 68.10% of the stock is owned by institutional investors.
Cardlytics Stock Down 8.1 %
NASDAQ CDLX opened at $3.16 on Thursday. The stock’s 50 day simple moving average is $3.65 and its 200 day simple moving average is $4.27. Cardlytics has a one year low of $2.76 and a one year high of $20.52. The firm has a market cap of $160.60 million, a PE ratio of -0.52 and a beta of 1.53. The company has a debt-to-equity ratio of 2.40, a current ratio of 1.18 and a quick ratio of 1.18.
Cardlytics (NASDAQ:CDLX – Get Free Report) last announced its earnings results on Wednesday, November 6th. The company reported ($0.15) EPS for the quarter, topping the consensus estimate of ($0.33) by $0.18. Cardlytics had a negative return on equity of 110.67% and a negative net margin of 93.55%. The company had revenue of $67.06 million for the quarter, compared to analysts’ expectations of $57.77 million. During the same quarter in the prior year, the business earned ($0.26) earnings per share. The business’s revenue for the quarter was down 15.1% on a year-over-year basis. As a group, sell-side analysts forecast that Cardlytics will post -1.52 earnings per share for the current fiscal year.
Cardlytics Company Profile
Cardlytics, Inc operates an advertising platform in the United States and the United Kingdom. It offers Cardlytics platform, a proprietary native bank advertising channel that enables marketers to reach customers through their network of financial institution partners through digital channels, such as online, mobile applications, email, and various real-time notifications; and Bridg platform, a customer data platform which utilizes point-of-sale data and enables marketers to perform analytics and targeted loyalty marketing, as well as measure the impact of their marketing.
See Also
- Five stocks we like better than Cardlytics
- Stock Market Upgrades: What Are They?
- How to Short Sell Stocks Like a Pro: Strategies and Tips
- The Basics of Support and Resistance
- 3 Steel Stocks Soaring After Tariff Announcements
- The 3 Best Fintech Stocks to Buy Now
- Top Analysts’ Picks for 2025: 3 of Morgan Stanley’s Favorites
Receive News & Ratings for Cardlytics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cardlytics and related companies with MarketBeat.com's FREE daily email newsletter.